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reduction of in-hospital events can be obtained with a strategy of
planned RA for selected lesions. However, this strategy does not affect
clinical outcomes at one year.
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BACKGROUND Stroke is a rare but serious adverse event associated to
PCI. However, the relative risk of stroke between stable patients un-
dergoing a direct PCI strategy and those undergoing OMT has not been
established yet.
METHODS We performed a meta-analysis of 6 contemporary ran-
domized control trials in which 5673 patients with SCAD were ran-
domized to initial PCI or OMT. Only trials with stent utilization more
than 50% were included. Study endpoint was the rate of stroke during
follow up.
RESULTS Mean age of patients ranged from 60 to 65 years and stent
utilization ranged from 72% to 100%. Rate of stroke was 2.0% at a
weighted mean follow up of 55.3 months. On pooled analysis, the risk
of stroke was similar between patients undergoing a PCI plus OMT and
those receiving only OMT (2.2% vs. 1.8%, OR on ﬁxed effect ¼ 1.24 95%
CI: 0.85-1.79). There was no heterogeneity among the studies (I2 ¼
0.0%, P ¼ 0.15). On sensitivity analysis after removing each individual
study the pooled effect estimate remains unchanged.xclusion
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direct PCI is not associated with an increased risk of stroke during
long-term follow up compared to an initial strategy based on OMT
alone.
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BACKGROUND The use of DES to treat patients with high-risk acute
coronary syndromes – HR-ACS (STEMI/NSTEMI) is increasing. How-
ever, controversies still exist related to their safety in this complex
patient population. Therefore, the aim of this study was to analyse 1-
year clinical outcomes of HR-ACS patients compared with stable pa-
tients (SP) presenting with stable angina or silent ischemia when
treated with one type of DES.
METHODS In the frame of large, prospective, single-arm, multicentre,
observational e-NOBORI registry, total of 3449 HR-ACS patients and
5149 SP patients were treated with bioresorbable polymer Nobori
DES. The primary endpoint of the study was target lesion failure (TLF)
deﬁned as composite of cardiac death (CD), target vessel related
myocardial infarction (TV-MI) and target lesion revascularization
(TLR). An independent clinical event committee adjudicated all
endpoint related events.
RESULTS Baseline characteristics revealed that patients with HR-ACS
were younger (62.812.5 vs 63.512.0 years; p¼0.01), were less
frequently diagnosed with diabetes (29.0% vs 33.8%; p<0.01), hy-
pertension (61.2% vs 77.5%; p<0.01), hyperlipidemia (54.1% vs 68.4%;
p<0.01) peripheral vascular disease (6.4% vs 9.5%; p<0.01), but were
more frequently current smokers (20.5% vs 36.4%; p<0.01). Addi-
tionally, fewer patients with HR-ACS had history of previous MI
(18.0% vs 32.3%; p<0.01), previous PCI (16.0% vs 36.0%; p<0.01) and
CABG (4.0% vs 7.9%; p<0.01). LAD was the most frequent target
vessel in both groups (44.8% vs 42.9%; p¼0.85). Radial access was the
more frequent in both groups, but signiﬁcantly higher in HR-ACS
patients (64.9% vs 52.4%; p<0.01). B2 type lesions were more
frequent ﬁnding in HR-ACS group (35.2% vs 31.6%; p<0.01) while C
type was more frequent in SP group (21.0% vs 22.5%; p¼0.04). As
expected, thrombus burden was higher in HR-ACS group (26.5% vs
2.1%l p<0.01), while lesions were less frequently ostial (9.8% vs
12.0%; p<0.01), at bifurcation (5.0% vs 6.9%; p<0.01) and calciﬁed
(28.4% vs 33.4%; p<0.01). One year mortality of any or cardiac causes
was signiﬁcantly higher in HR-ACS group (2.6% vs 1.3% and 1.8% vs
0.9%; p<0.01 for both) who also had higher MI rate (1.8% vs 1.1%;
p<0.01). The frequency of target lesion (1.6% vs 1.3%; p¼0.24) and
target vessel revascularization (2.1% vs 1.9%; p¼0.47) showed no
signiﬁcant difference between the two groups. Composite rate of TLF(4.2% vs 3.0%; p<0.01), TVF (4.6% vs 3.4%; p<0.01) and deﬁnite and
probable stent thrombosis (0.9% vs 0.4%; p<0.01), were all higher in
HR-ACS group.
CONCLUSIONS The rate of adverse events was low in both groups of
patients in this all-comers, unselected patient groups, but as ex-
pected, was higher event rates occurred in HR-ACS patients. Based on
our data the bioresorbable polymer DES seems to be appropriate for
both, high risk acute coronary syndromes and stable patients,
providing very good safety and efﬁcacy proﬁle.
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BACKGROUND Percutaneous coronary intervention (PCI) with drug-
eluting balloons (DEB) has emerged as an adjunctive treatment for
instent restenosis lesion. When compared to drug-eluting stents
(DES), DEBs offer advantages such as immediate and homogeneous
drug release in the arterial wall, absence of polymers that can induce
chronic inﬂammatory reactions. However, repeat restenosis still exist
after DEB use. Our study aimed to ﬁnd out the predictors of repeat
instent restenosis after DEB use during one-year clinical follow-up.
METHODS From November 2011 to May 2014, 246 patients were
diagnosed as coronary artery in-stent restenosis in our hospital. Total
335 coronary in-stent restenosis lesions were treated by DEBs. We
compared demographics, risk factors, lesion site, characteristic of
coronary artery disease, previous stent and intravascular ultrasound
(IVUS) use between one-year patent group and one-year repeat in-
stent restenosis group. One-year coronary artery patent group was
deﬁned as negative non-invasive examination or no clinical symp-
toms. Univariate and multivariate logistic regression analyses were
performed to identify predictors of repeat in-stent restenosis after
DEB use.
RESULTS The average age of the patients was 64.96  10.68 years,
with a range of 29 to 91 years, and 77.2% of the patients were male.
One-year repeat in-stent restenosis group had more favorable as non
ST segment elevation myocardial infarction, less favorable as stable
angina. One-year repeat in-stent restenosis group had higher per-
centage of co-morbidities such as hypertension, diabetes, old
myocardial infarction, heart failure, prior coronary artery bypass
grafting and end stage renal disease (ESRD) on maintenance hemo-
dialysis. More ostial lesion (30.5% vs. 46.2%, p¼0.122) and more left
main bifurcation lesion (19.1% vs. 26.9%, p¼0.434) were in one-year
repeat in-stent restenosis group. Characteristics of coronary artery
disease were similar between two groups and many patients had
multiple vessel disease. Previous bare metal stent (BMS) use was
dominant in one-year patent group (55%) and previous DES use was
dominant in one-year repeat in-stent restenosis group (65.4%). IVUS
use was higher in one-year patent group. Only one case had PCI
related complication such as balloon-jailed side branch vessel in one-
year patent group. Multivariate analysis revealed that only ESRD on
maintenance hemodialysis and coronary ostial lesion were indepen-
dent predictors of repeat in-stent restenosis after DEB use (p¼0.034;
p¼0.016; respectively).
